stockrowOrganon & Co.
OGNHealthcare Drug Manufacturers General
Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.
- Revenue
- −1.75%
- EPS
- +1.64%
- Free cash flow
- +118.8%
- Total debt
- −3.10%
Quarter to September 2026, against a year earlier
Follow OGN
Alert me
Organon & Co. (OGN) Net income
Organon & Co.'s net income for fiscal 2025 was $187.0M, down 78.4% from $864.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was $213.0M. Over the past ten years it has ranged from $0.00 (fiscal 2021) to $3.3B (fiscal 2019); the current reading is higher than 33% of that period. Organon & Co. ranks 15th of 21 Drug Manufacturers General companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $187.0M | (78.36%) |
| FY2024 | $864.0M | (15.54%) |
| FY2023 | $1.0B | 11.56% |
| FY2022 | $917.0M | — |
| FY2021 | $0.00 | — |
| FY2020 | $2.3B | (31.76%) |
| FY2019 | $3.3B | 53.55% |
| FY2018 | $2.2B | — |
| FY2017 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $164.0M | 51.85% |
| Jun 2026 | $108.0M | (26.03%) |
| Mar 2026 | $146.0M | — |
| Dec 2025 | −$205.0M | — |
| 25 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| NVO Novo Nordisk A/S compare | $17.0B |
| BMY Bristol Myers Squibb Company compare | $9.2B |
| GSK GSK PLC Sponsored ADR compare | $6.3B |
| SNY Sanofi compare | $4.5B |
| PFE Pfizer Inc. compare | $4.1B |
| GRFS Grifols, S.A. compare | $789.6M |
| BIIB Biogen Inc. compare | $347.5M |
| OGN Organon & Co. | $213.0M |
| AMRN Amarin Corporation PLC compare | −$19.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on OGN
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement